Efficacy and safety of pegzilarginase in patients below 2 years of age with arginase 1 deficiency: a phase 3, open-label, multi-centre study.

Ghosh A, Baghdasaryan A, Pinto PL, Rudebeck M

Open source

DOI
10.1016/j.eclinm.2026.104021
Published
2026 Jul
Container
EClinicalMedicine
Publisher
Not recorded
Open access
yes

Credibility signals

limited evidence Score 45/100 under policy 1.0.0. This is a metadata assessment, not a judgment of the paper's conclusions.

Show all credibility signals

Cite this work

BibTeX

@article{allodium:10.1016/j.eclinm.2026.104021,
  title = {Efficacy and safety of pegzilarginase in patients below 2 years of age with arginase 1 deficiency: a phase 3, open-label, multi-centre study.},
  author = {Ghosh A and Baghdasaryan A and Pinto PL and Rudebeck M},
  year = {2026},
  journal = {EClinicalMedicine},
  doi = {10.1016/j.eclinm.2026.104021},
  url = {https://doi.org/10.1016/j.eclinm.2026.104021}
}

RIS

TY  - JOUR
TI  - Efficacy and safety of pegzilarginase in patients below 2 years of age with arginase 1 deficiency: a phase 3, open-label, multi-centre study.
AU  - Ghosh A
AU  - Baghdasaryan A
AU  - Pinto PL
AU  - Rudebeck M
PY  - 2026
JO  - EClinicalMedicine
DO  - 10.1016/j.eclinm.2026.104021
UR  - https://doi.org/10.1016/j.eclinm.2026.104021
ER  - 

APA

A, G., A, B., PL, P., & M, R. (2026). Efficacy and safety of pegzilarginase in patients below 2 years of age with arginase 1 deficiency: a phase 3, open-label, multi-centre study.. EClinicalMedicine. https://doi.org/10.1016/j.eclinm.2026.104021

Source records